Sign in
CompletedPhase 4

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Key facts

Who runs it
Shandong University
Where
China6 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
406 people enrolled
Started
1 Jul 2022
Ended
1 Feb 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Amoxicillin
  • Tetracycline tid
  • Tetracycline qid
  • Bismuth Potassium Citrate
  • Colloidal Bismuth Pectin
  • Esomeprazole 20mg
Record updated
27 March 2024

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients aged 18-70
  • Patients with H.pylori infection (Positive for rapid urease test or 13C/14C-urea breath test)
  • Patients who have never received H. pylori eradication treatment

Who cannot take part

  • Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than 1.5 times the normal value), renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate <50 ml/min), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%
  • Patients with active gastrointestinal bleeding
  • Patients with a history of upper gastrointestinal surgery
  • Patients allergic to treatment drugs
  • Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks
  • Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse
  • Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial
  • Patients who are unwilling or incapable to provide informed consents

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

The 2 groups in the trial

  • Tid groupTreatment being tested

    Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 20mg bid

    Treatment: Amoxicillin, Tetracycline tid, Bismuth Potassium Citrate, Colloidal Bismuth Pectin, and Esomeprazole 20mg

  • Qid groupExisting treatment, for comparison

    Qid group: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 20mg bid

    Treatment: Amoxicillin, Tetracycline qid, Bismuth Potassium Citrate, Colloidal Bismuth Pectin, and Esomeprazole 20mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.
Publications
Record updated
27 March 2024